Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Argus Health
US Department of Justice
Daiichi Sankyo

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,814,168

« Back to Dashboard

Summary for Patent: 4,814,168

Title: Transdermal multipolymer drug delivery system
Abstract:A dermal compositon comprising a drug, a multi-polymer of vinyl acetate, polyethylene and optionally one or more monomers, a natural or synthetic rubber and a tackifying agent. The ratio of the multipolymer to the rubber is, respectively, about 1:1 to about 10:1 and more preferably 1:1 to 5:1 and more preferably 3:1. The dermal composition can optionally contain a crosslinking agent, tackifiers, penetration enhancers and other ingredients known for use in adhesives for the transdermal delivery of drugs. The dermal compositions can be produced by a variety of methods known in the preparation of drug containing adhesive preparations including the homogenous mixing of the multi-polymer, drug and optional crosslinking agent and additional ingredients in aqueous solution followed by removal of excess water.
Inventor(s): Sablotsky; Steven (Miami, FL), Questel; John M. (Cuyahoga Falls, OH), Leeson; Dorothy J. (North Canton, OH)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Application Number:07/164,482
Patent Claim Types:
see list of patent claims

No matches for this query

International Patent Family for Patent: 4,814,168

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2044132► Subscribe
Canada1338660► Subscribe
Canada2025033► Subscribe
Brazil9506470► Subscribe
Canada2044170► Subscribe
Canada2104474► Subscribe
Canada2109099► Subscribe
Canada2110914► Subscribe
Canada2126366► Subscribe
Canada2170504► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus